Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Published:2015-07 Issue:7 Volume:16 Page:859-870
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zhu Andrew X,Park Joon Oh,Ryoo Baek-Yeol,Yen Chia-Jui,Poon Ronnie,Pastorelli Davide,Blanc Jean-Frederic,Chung Hyun Cheol,Baron Ari D,Pfiffer Tulio Eduardo Flesch,Okusaka Takuji,Kubackova Katerina,Trojan Jorg,Sastre Javier,Chau Ian,Chang Shao-Chun,Abada Paolo B,Yang Ling,Schwartz Jonathan D,Kudo Masatoshi

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Long interval between HCV infection and development of hepatocellular carcinoma;Castells;Liver,1995

3. Diagnosis of hepatocellular carcinoma;Gomaa;World J Gastroenterol,2009

4. Staging systems in hepatocellular carcinoma;Pons;HPB (Oxford),2005

5. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

Cited by 745 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapies for Hepatocellular Carcinoma in India;Journal of Clinical and Experimental Hepatology;2024-11

2. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

3. Targeted therapies in hepatocellular carcinoma: past, present, and future;Frontiers in Oncology;2024-08-29

4. Phase I–IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies;International Journal of Molecular Sciences;2024-08-27

5. Advancements in second-line treatment research for hepatocellular carcinoma;Clinical and Translational Oncology;2024-08-20